An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients. This study is no longer actively recruiting.


Lung cancer is the leading cause of cancer death in Australia and worldwide, with a five-year survival rate of only 17 per cent.


The ASPiRATION program is a pioneering partnership between Government, industry and academia. The program is led by the Thoracic Oncology Group of Australasia (TOGA) [formerly the Australasian Lung Cancer Trials Group (ALTG)] in collaboration with Omico and the NHMRC Clinical Trials Centre (CTC). The program is supported by funding from the federal government’s Medical Research Future Fund (MRFF) and Roche.


The ASPiRATION study is the first of its kind in Australia to generate high-quality, real-world data about the impact and value of comprehensive genomic profiling (CGP) in delivering precision medicine and personalised healthcare. Identifying actionable molecular targets through CGP provides patients with opportunities to receive novel targeted treatments via therapeutic substudies.


Molecular screening for ASPiRATION commenced in late 2020, with expansion to 15 participating hospitals throughout Australia by mid 2021.

1000 participants were recruited over a 2.5 years period, from 23 December 2020 to 21 June 2023.

Four of the five substudies have closed to recruitment.

find an open ASPiRATION site


For further information contact

For progress on ethics and governance and study start up in your state, clinicians can contact the NHMRC Clinical Trial Centre via